$ALGN

ALGN Q2 Deep Dive: Clear Aligner Volumes Grow, Guidance Flags Scanner Mix Shift

Align Technology reported Q2 revenue of $1.06B vs $1.05B expected and adjusted EPS of $2.64 vs $2.60. Adjusted operating income was $241.7M. Sales volumes rose 7.4% YoY, but Q3 CY2026 revenue guidance midpoint was $1.01B vs $1.02B estimates. Margin fell to 14.6%.

Original reporting
Published Aug 4, 2026, 10:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 11:12 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ALGN Q2 Deep Dive: Clear Aligner Volumes Grow, Guidance Flags Scanner Mix Shift — source image
Decision brief

The 30-second read

$ALGNNeutralMed
01

Why it matters

Traders should focus on the combination of (1) Q3 revenue guidance below consensus, (2) operating margin down year over year, and (3) management’s explicit expectation that scanner mix headwinds persist into 2027, despite longer-term installed-base benefits.

02

Market read

This is a guidance-and-margins story: earnings beat and volumes rise, but the Q3 revenue midpoint and margin trend introduce near-term caution.

03

What to watch

The article notes a strategic review after Elliott Management discussions; execution changes could alter the cost trajectory and commercial effectiveness beyond what the near-term guidance implies.

Relevance 7/10Novelty 7/10Timing: post-earnings, pre-Q3 positioning

Background

Align’s Q2 results emphasize clear aligner volume growth and international momentum, while the scanner business is transitioning toward lower-priced configurations and more leasing/rental options.

Company-level read

Ticker impact

$ALGNNeutralMedium confidence
Context

Align reports Q2 revenue and EPS beats, but guides Q3 revenue to $1.01B midpoint below consensus and flags margin pressure from scanner mix.

Expected impact

Choppy-to-soft bias into Q3 as investors weigh the guidance miss and margin headwinds against volume growth and international momentum.

Evidence & confidence

The article’s newest decision-relevant facts are the Q3 revenue guidance midpoint below estimates and operating margin down year over year, both directly tied to management’s scanner business model transition and capital equipment weakness.

Market effects

Clear aligner peers may face read-across on scanner monetization and recurring revenue tradeoffs as customers shift toward lower-priced and leased scanner models.

International growth (APAC, EMEA, Latin America) is highlighted as a partial offset to North America retail improvement needs.

Dental digital workflow adoption and financing/subscription models remain a key demand lever, with mix effects expected to persist into 2027.

Counterpoint

The Q3 revenue guide miss could be more than offset by accelerating adoption from financing and subscription programs, with margin pressure largely transitional from scanner mix.

Key entities

  • Align Technology

    Reports Q2 beats, guides Q3 revenue slightly below consensus, and discusses scanner mix transition and margin pressure.

  • Joe Hogan

    CEO highlights strong uptake across adult and teen segments and international clear aligner momentum.

  • Elliott Management

    Referenced as having discussions with Align that preceded a strategic and operating model review.

  • John Morici

    CFO discusses gross margin drivers and operating expense discipline initiatives.

Related articles

$ALGNLow

Align Tech adds Quentin Blackford to board

Align Technology (ALGN) added Quentin Blackford, CEO of iRhythm Technologies, to its board, expanding it to 11 members. Blackford brings healthcare and digital innovation experience. Director Andrea L. Saia will retire in September 2026, reducing the board to 10 members.

$ALGNMed

Are Wall Street Analysts Bullish on Align Technology Stock?

Align Technology (ALGN), a medical device company, has underperformed the broader market and healthcare sector ETF over the past 52 weeks. Analysts expect its adjusted EPS to grow 10.9% YoY by 2026, with a consensus 'Moderate Buy' rating. The mean price target is $207.07, implying a 30.1% upside. Piper Sandler maintained a 'Buy' rating with a $235 target.

$ALGNMed

Align Technology Prevails in China Patent Infringement Action Against Angelalign

Align Technology said a Jinan Intermediate People’s Court issued a first-instance ruling on Aug. 10, 2026 in a China patent case against Angel. The court found Angel’s MasterForce and ATreat systems infringe Align’s CN113693748B patent and ordered Angel to stop use, manufacturing, and sales, awarding RMB 10 million in damages. Angel can appeal to China’s Supreme People’s Court.

$ALGNMed

Align Technology, Inc.: Align Technology Prevails in China Patent Infringement Action Against Angelalign

Align Technology (Nasdaq: ALGN) said China’s Jinan Intermediate People’s Court ruled in its favor in a patent infringement case against Angelalign’s China subsidiaries. The court found Angel infringed Align’s CN113693748B patent tied to extraction-gap-closure technology, ordering a stop to use and sales in China and awarding RMB 10 million in damages. Angel can appeal.

$DDDMed

3D Printing Financials: 3D Systems, Prodways, and Align Build on Positive Momentum - 3DPrint.com

3D Systems reported Q2 revenue of $94.6M, flat YoY, with healthcare up 6.8% and aerospace/defense and data center infrastructure each growing over 20%. Adjusted EBITDA loss narrowed to $0.8M. It expects Q3 revenue of $96M to $99M. Prodways posted Q2 revenue of €10.5M (+5% YoY) and plans a €20M buyback. Align Technology reported record Q2 revenue of just over $1.05B (+4.3%), with clear aligner revenue up 8.2% and 2026 revenue growth guidance of 3% to 4%.

$ALGNMedAI 9/10

Align Technology (ALGN) Q2 2026 Earnings Call Transcript

Align Technology (ALGN) reported Q2 2026 revenue of $1,056.2 million, up 4.3% y/y, driven by record Clear Aligner volumes and higher ASPs. Clear Aligner revenue rose 8.2% to $870.9 million on 691,785 cases. Systems and Services revenue fell 10.8% to $185.3 million. Q3 revenue guidance is $1.00 to $1.02 billion; full-year growth 3% to 4%.